Title in Capitalize Each Word Case, Bolded (Limit to ~2 lines of text)

Short Title: Short Title in Capitalize Each Word Case, italics (if needed)

Author 1, degree(s)1,2; Author 2, degree(s)1,3; Author 3, degree(s)4; …; Steven M. Smith, PharmD, MPH1,X,Y

1Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA;

2Department of …, College of …, University of …, City, STATE, COUNTRY;

XCenter of Drug Evaluation and Safety, University of Florida, Gainesville, FL, USA

YCenter for Integrative Cardiovascular and Metabolic Disease, Gainesville, FL, USA

Corresponding Author:

Dr. Steven M. Smith, PO Box 100496, Gainesville, FL 32610-0496; tel 352-273-5134; email ssmith@cop.ufl.edu

Word Count: XXX (main text excl. refs), XXX (abstract); X table(s); X figure(s); 1 supplement

ABSTRACT (≤250 words unless journal says otherwise)

Background: 1-2 sentences describing background and rationale

Methods: Briefly describe the broad strokes of the methods.

Results: First sentence (or two) describes the population. Then, follow-up with brief description of the most important findings (at a high level) – there’s not a lot of room for detail, so don’t try to include everything.

Conclusions: 2-3 sentences summarizing implications of the results, and any need for future research in this area.

Keywords: 3-5 key words that are relevant to the manuscript
NON-STANDARD ABBREVIATIONS AND ACRONYMS

ACEI, angiotensin-converting enzyme inhibitor

ARB, angiotensin receptor blocker

ASCVD, atherosclerotic cardiovascular disease

BP, blood pressure

CCB, calcium channel blocker

CKD, chronic kidney disease

DHP, dihydropyridine

EHR, electronic health record

HF, heart failure

ICD, International Classification of Diseases

NDC, National Drug Code

NHANES, National Health And Nutrition Examination Survey

PCORnet, Patient-Centered Outcomes Research network

SMD, standardized mean difference

(edit the above list as needed and remove this line)

INTRODUCTION

The introduction of your article should be a gambit, approximately 1-1.25 pages, double-spaced, in length (try hard not to exceed 1.5 pages, double-spaced).

METHODS

We conducted a <<type>> study of <<topic>> using patient-level data from <<data source>> from <<dates>>. The study was approved by the University of Florida Institutional Review Board, with a full waiver of informed consent for research involving data previously collected for non-research purposes. Data underlying this study may be obtained <<mechanism>> by qualified researchers trained in human subject confidentiality protocols and subsequent to execution of a data use agreement.

Data Source

Description of data source…

Participants and Cohort Development

Description of cohort development. If tables or figures are helpful in summarizing this information, include them in the data supplement.

Data Collection

Baseline characteristics were measured during the baseline period (generally 1 year prior to and including index date), as per the definitions summarized in Table S2. Additional details …

Data Analysis

We summarized baseline characteristics using mean and standard deviation for continuous variables and n (%) for categorical variables in the overall study population and stratified by <<stratification criteria>>. Rest of the analysis details… All data were analyzed with SAS 9.4 (SAS Institute, Cary, NC, USA) / R 4.2.X (R Foundation, Vienna, Austria) / other.

RESULTS

We identified a total of XX patients with <<main inclusion criteria>> … (Figure SX [this is your flow diagram as a supplemental figure]). Baseline characteristics of the cohort are summarized in Table 1. Briefly, patients were aged XX years on average and XX% were women. (And so on (incl. race, ethnicity, important comorbidities, etc… For example: A plurality of patients self-reported as White (49% overall; Medicaid, 35% vs. Medicare, 63%), 24% (Medicaid, 31%; Medicare, 17%) as Black or African American, and 12% had missing race information; 16% (Medicaid, 18%; Medicare, 14%) were Hispanic. The most common comorbidities were diabetes (21%) and depression (18%), and nearly one-quarter were current smokers. Chronic kidney disease and ASCVD were considerably more common in the Medicare versus Medicaid population.)

Results Topic #1

…

Results Topic #2

…

Stratified Analyses: …

…

Sensitivity Analyses

…

DISCUSSION (try to keep this to ~4 pages double-spaced, give or take)

First paragraph summarizes (briefly) need for study, what we found, and importance/innovativeness of the study.

Next several paragraphs go into individual findings of importance, and places them in the context of prior knowns/literature/gaps. Where possible/appropriate, include data supporting mechanisms for findings, or even data that help us speculate on why we might have found what we found.

Then, a strengths & limitations paragraph. Start with strengths (few sentences at most). Then, each limitation should be stated, and then if appropriate, add a rebuttal for why this limitation is unlikely to have made a large (negative) impact on our findings.

Then a summary paragraph.

Funding (here’s an example paragraph – talk to Dr. Smith about what needs to be included)

This work was funded by the National Heart, Lung, and Blood Institute, K01 HL138172 (Dr. Smith). Research reported in this publication was also supported in part by the UF Center for Drug Evaluation and Safety; in part by the OneFlorida Clinical Data Network, funded by the Patient-Centered Outcomes Research Institute numbers CDRN-1501-26692 and RI-CRN-2020-005; in part by the OneFlorida Cancer Control Alliance, funded by the Florida Department of Health’s James and Esther King Biomedical Research Program number 4KB16; and in part by the University of Florida Clinical and Translational Science Institute and its Clinical and Translational Science Award (CTSA) hub partner, Florida State University, which are supported in part by three CTSA Program grants awarded on August 15, 2015, and renewed for five years on July 2, 2019, by the National Center for Advancing Translational Sciences of the National Institutes of Health. The UF-FSU CTSA grant numbers are UL1TR001427, KL2TR001429 and TL1TR001428. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, Patient-Centered Outcomes Research Institute (PCORI) or its Board of Governors or Methodology, the OneFlorida Clinical Research Consortium, the UF-FSU Clinical and Translational Science Institute, or the Florida Department of Health.

Disclosures

The authors have no conflicts of interest to disclose.

Supplemental Materials (edit, as needed)

Methods

Tables S1-SX

Figures S1-SX
REFERENCES

Use reference software – Mendeley, Zotero, or Endnote

FIGURE LEGENDS

Figure 1. Title. Additional information to aid interpretation… ABBREVIATION1, meaning; ABBREVIATION2, meaning; ….

Figure 2. Title. Additional information to aid interpretation… ABBREVIATION1, meaning; ABBREVIATION2, meaning; ….

Figure 3. Title. Additional information to aid interpretation… ABBREVIATION1, meaning; ABBREVIATION2, meaning; ….

…

Table 1. Title. (adjust table specifics to the study – the below is just an example)

Baseline Characteristics	Overall Cohort (N=XXX)	Strata 1 Cohort (N=XXX)	Strata 2 Cohort (N=XXX)	SMD†
Age (years)	XX ± YY	XX ± YY	XX ± YY	XX
Age category 1	n (%)	n (%)	n (%)
Age category 2	n (%)	n (%)	n (%)
…	n (%)	n (%)	n (%)
Sex	XX
Female	n (%)	n (%)	n (%)
Male	n (%)	n (%)	n (%)
Missing	n (%)	n (%)	n (%)
Race	XX
American Indian or Alaska Native	n (%)	n (%)	n (%)
Asian	n (%)	n (%)	n (%)
Black or African American	n (%)	n (%)	n (%)
Native Hawaiian or Other Pacific Islander	n (%)	n (%)	n (%)
White	n (%)	n (%)	n (%)
Multiple Race	n (%)	n (%)	n (%)
Other	n (%)	n (%)	n (%)
Unknown	n (%)	n (%)	n (%)
Ethnicity	XX
Hispanic	n (%)	n (%)	n (%)
Non-Hispanic	n (%)	n (%)	n (%)
Unknown	n (%)	n (%)	n (%)
Missing	n (%)	n (%)	n (%)
Comorbidities
Current Smoker	n (%)	n (%)	n (%)	XX
Diabetes	n (%)	n (%)	n (%)	XX
Chronic kidney disease	n (%)	n (%)	n (%)	XX
End-stage renal disease	n (%)	n (%)	n (%)	XX
HF with reduced EF	n (%)	n (%)	n (%)	XX
Coronary heart disease	n (%)	n (%)	n (%)	XX
Prior coronary revascularization	n (%)	n (%)	n (%)	XX
Prior stroke or TIA	n (%)	n (%)	n (%)	XX
Peripheral arterial disease	n (%)	n (%)	n (%)	XX
History of clinical ASCVD	n (%)	n (%)	n (%)	XX
Atrial fibrillation	n (%)	n (%)	n (%)	XX
COPD	n (%)	n (%)	n (%)	XX
Asthma	n (%)	n (%)	n (%)	XX
Depression	n (%)	n (%)	n (%)	XX
Combined Comorbidity Score	mean ± sd	mean ± sd	mean ± sd	XX
Other Medication Use
Drug A	n (%)	n (%)	n (%)	XX
Drug B	n (%)	n (%)	n (%)	XX
Index Year
2012	n (%)	n (%)	n (%)
2013	n (%)	n (%)	n (%)
2014	n (%)	n (%)	n (%)
2015	n (%)	n (%)	n (%)
2016	n (%)	n (%)	n (%)
2017	n (%)	n (%)	n (%)
2018	n (%)	n (%)	n (%)
2019	n (%)	n (%)	n (%)
2020	n (%)	n (%)	n (%)
2021	n (%)	n (%)	n (%)
*Footnote 1. †Footnote 2. ACRONYM1 indicates meaning1; ACRONYM2, meaning2; ACRONYM3, meaning3; …

Figure 1. Title. Additional details. ACRONYM1, meaning1; ACRONYM2, meaning2; … (this text should match the text on the figure legends page)

<<Figure>>

Figure 2. Title. Additional information. ACRONYM1, meaning1; ACRONYM2, meaning2; … (this text should match the text on the figure legends page)

<<Figure>>